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Summary There is evidence from previous studies of small numbers of children who received cytotoxic
therapy for cancer, that they may develop increased numbers of melanocytic naevi (moles), the strongest
known risk factors for melanoma. Our aim was to investigate a large number of survivors of childhood cancer
in order to test the hypothesis that they have more melanocytic naevi than matched controls. Total-body
naevus counts were obtained from 263 oncology patients ascertained in paediatric oncology departments in
Queensland, Australia, and from 263 hospital controls matched for age and sex. Additional information was
gathered from children's parents about concurrent factors influencing naevus development such as type of
complexion and history of sun exposure. Matched analyses, both crude and adjusted for possible confounding
factors, revealed no significant difference in overall density of naevi among oncology patients and control
subjects, according to diagnosis or to duration or type of chemotherapy. However significantly more oncology
patients had atypical naevi (P<0.05) and acral naevi (P<0.0001) than controls. One patient developed a
malignant melanoma 13 years after chemotherapy and radiotherapy for rhabdomyosarcoma. These findings
support an association between treatment for childhood cancer and acral naevi and suggest that atypical naevi
may also be associated with chemotherapy in childhood.
The numbers of long-term survivors of childhood cancer
worldwide are now substantial, and in the United States it
has been estimated that one out of every 1,000 young adults
is a cancer survivor (Meadows et al., 1980). In general chil-
dren diagnosed with leukaemia and other cancers have an
increased risk of developing a second malignancy during or
after therapy, and both genetic and treatment factors have
been implicated (Ochs & Mulhern, 1988). There is some
evidence that increased numbers of benign melanocytic naevi
(moles) also develop in long-term survivors of childhood
cancer who have received cytotoxic therapy. Large numbers
of acquired melanocytic naevi are the strongest known risk
factors for melanoma (Green & Swerdlow, 1989). The first
suggestions of this possible association with chemotherapy
came from case reports concerning the development of naevi
in children treated with standard cytostatic and immunosup-
pressive regimens, and mercaptopurine (Ippen & Prindull,
1984); in a monozygotic twin (Heyne et al., 1984; Hughes &
Bailey, 1989) and in a 12-year-old boy treated with pred-
nisolone and azathioprine therapy after renal transplantation
(Barker & MacDonald, 1988).
While such case reports cannot establish aetiology, a case-
control study in England (Hughes et al., 1989) provided for
the first time some epidemiologic evidence of a possible
aetiologic role of chemotherapeutic agents in naevus forma-
tion. Hughes et al. (1989) compared 32 patients who were
receiving chemotherapy and 32 patients who had successfully
completed therapy, with 32 controls from dermatology out-
patient clinics. They found similar numbers of naevi both
<3 mm and > 3 mm diameter in children on maintenance
chemotherapy and controls, but a significant increase in
naevi among patients who had successfully completed chemo-
therapy. Acral naevi (occurring on palms and soles), which
are generally uncommon, were increased in both groups of
oncology patients. In another study in The Netherlands (de
Wit et al., 1990), the median number of naevi in subjects who
had received chemotherapy for childhood cancer was found
to be increased (P<0.05), this time in comparison with
siblings. A recent study in Glasgow showed that total body
naevus counts were significantly increased in 22 children who
were followed-up 3 years after starting maintenance chemo-
therapy for leukaemia (Baird et al., 1992), though compar-
ison median naevus counts were only available according to
decade of age for children assessed in a separate cross-
sectional study (MacKie et al., 1985).
In healthy children melanocytic naevi are associated with
fair complexion and solar ultraviolet (UV) exposure (Green
et al., 1989; Gallagher et al., 1990), perhaps with additional
hormonal influences around puberty (Green & Swerdlow,
1989). However there is increasing experimental and clinical
evidence that UV radiation perturbs the immune system
(Streilein, 1991), suggesting that immunosuppression, in gen-
eral, may be involved in the aetiology of naevi.
Confirmation of a causal link between naevi and cytotoxic
therapy during childhood would have far reaching impli-
cations, namely that the increasing numbers of children suc-
cessfully treated for leukaemia or other cancer may be at
considerably increased risk of melanoma. This is of concern
especially in populations in which the baseline risk of melan-
oma is relatively high and increasing rapidly, such as in
Britain (MacKie et al., 1992) and Australia (MacLennan et
al., 1992). We therefore investigated the relation between
cytotoxic therapy and the development of melanocytic naevi,
with particular interest in acral naevi, in over 200 children in
Queensland, Australia, where some of the highest incidence
rates of cutaneous melanoma have been reported (MacLen-
nan et al., 1992).
Methods
Subjects
Patients who had received chemotherapy for childhood can-
cer in Queensland until the end of 1990 were eligible for
inclusion in the study. They were ascertained through the
oncology departments of the Royal Children's Hospital and
the Matar Misericordiae Children's Hospital in Brisbane, and
through the Townsville General Hosital which serves the
state's northern region. A standard surveillance protocol is
routinely used by all paediatric oncologists at these hospitals,
which enabled ascertainment of any of their patients from
commencement of treatment to post-therapy surveillance.
Controls matched for age (within 1 year), sex and hospital
were drawn at random from children admitted for routine
ear, nose and throat, orthopaedic and general surgical proce-
dures. Those who had received regular corticosteroid therapy
or any other form of immunosuppressive therapy were ex-
cluded.
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Data collection
Children's parents gave signed consent and were interviewed
using a standard questionnaire to obtain details about sun
exposure history in their children including usual time out-
doors during the week, on weekends and on holidays;
number of visits to the beach in the previous 2 years; usual
use of sun protection measures such as sunscreen when in the
sun; and number of severe sunburns causing pain for at least
24 h. Details were gathered about phenotypic risk factors for
naevi, including tendency to freckle; skin, eye and hair col-
our; and tendency to burn after acute sun exposure. Family
history of melanoma was also noted. Each child's diagnosis
was recorded and details of any chemotherapeutic regimen
including dates of commencement and completion, and
drug protocol. Height and weight were obtained to enable
calculation of skin surface area (SA) using the formula
(SA = / (height x weight)/3600) (Mosteller, 1987).
Total numbers of melanocytic naevi > 2 mm diameter, flat
or raised, were counted in both groups with the aid of a
stencil, and were recorded on a whole body map according to
a standard protocol (Green et al., 1989). Atypical naevi,
defined as naevi with at least two of the following: diameter
5 mm or greater; variegate colour; atypical morphology
(irregular or ill-defined border), were also recorded. Naevus
counts were performed by two research nurses trained in the
identification of pigmented lesions in children. To check re-
producibility, independent total-body counts were performed
on nine subjects by both nurses, and these counts were found
to be highly correlated (P= 0.93, P<0.001). Number of
naevi on the interviewed parent's arms (the mother's arms for
90% of children in the study) were also counted using the
same criteria. Skin reflectance measures were taken on the
left forearm (exposed site) and left axilla (unexposed) of each
child.
Data analysis
Naevus density (naevus count per square metre of body
surface area) was calculated for each subject. Due to the
matched study design, ratios of naevus densities between
oncology patients and matched controls were the outcome
variables of interest. Given the skewed frequency distribu-
tions of these ratios, the sign test (Conover, 1980) was used
to determine whether the ratios of paired median densities
were significantly different from one. To assess the effects of
chemotherapeutic agents and duration of chemotherapy on
naevus densities among oncology patients according to age
and sex, Kruskal-Wallis analysis of variance was used. Due
to the low numbers of naevi on acral sites, detailed analyses
were also carried out based on their presence or absence as
well as corresponding naevus densities, and univariate
differences in proportions of oncology patients and controls
with acral naevi were assessed using the McNemar test.
Multiple linear regression was used to model the matched
comparisons of naevus densities, controlling for the effects of
potentially confounding phenotyopic and sun exposure varia-
bles, namely skin colour, propensity to freckle, history of
sunburn, and time spent outdoors on weekends. The relative
odds of having had chemotherapy as a function of the
presence of acral naevi was considered using conditional
logistic regression (Breslow & Day, 1980). Interobserver cor-
relation was calculated using the Spearman correlation
coefficient.
Results
Study population
A total of 263 patients (103 females) were enrolled through
paediatric oncology departments, representing 90% of those
eligible. Of the 33 patients who were not enrolled, there were
27 for whom an interview with their parents could not be
arranged, two refusals, and four children who were too sick.
In addition, two non-Caucasian children (one Aboriginal
child and one Asian child) were not included. The median
age ofthe sample was 8.2 years (range 6 months to 23 years).
Among oncology patients, 155 (59%) had leukaemia and the
remainder included 23 patients with Wilms' tumour (9%); 11
with rhabdomyosarcoma (5%); 12 with non-Hodgkin's lym-
phoma (4%); 12 with Ewing's sarcoma (5%); and 50 (19%)
with other malignancies. At time of enrolment, 101 children
(38%) were commencing or still receiving chemotherapy,
leaving 162 (62%) who had completed treatment. Of the
children still receiving chemotherapy, 30% had been treated
for more than 12 months, compared to 70% of those success-
fully treated. The average time that had elapsed since com-
pletion of therapy in the latter group was 28 months. Among
the 263 controls without a history of cancer who were drawn
from surgical wards, matched for age, sex and treating hos-
pital, 168 (64%) were admitted for routine ear, nose and
throat surgery, 31 (12%) for orthopaedic surgery, and the
remainder for miscellaneous surgical procedures. Among all
controls approached there was one refusal.
Regarding type of complexion of study subjects, controls
tended to have fairer skins as measured by skin reflectance, a
greater tendency to freckle, and more sunburns, compared to
oncology patients; controls also tended to spend more time
outdoors on weekends and holidays (these were highly cor-
related). There were no significant differences between onco-
logy patients and controls in use of sunscreen, hair colour,
number of visits to the beach in the last 2 years, time
outdoors during the week, or family history of melanoma. As
might be expected, oncology patients reported hat-wearing
more frequently than controls.
Naevus density after chemotherapy
The median whole-body naevus density in those who had
received chemotherapy was 21.5 naevi m-2 compared to 19.5
in controls (Table I) corresponding to median whole-body
naevus counts of 22.0 and 21.0 in oncology patients and
controls respectively. Males who had been treated for cancer
had slightly higher naevus densities than controls (paired
ratio = 1.1) but this difference was not significant. Also there
were no significant differences according to age or type of
cancer, though children treated for Wilms' tumour appeared
to have a relative deficit compared to controls (Table I).
Density of naevi in oncology patients did not vary
significantly with whether treatment was ongoing or had been
completed, with duration of chemotherapy, or with duration
of remission, and there was no variation in density of naevi
in oncology patients according to whether a particular treat-
ment was received (Table I).
Because the distribution of naevi is not uniform over the
body, naevi among cancer survivors was analysed by ana-
tomic region, namely head and neck, trunk, arms, legs and
acral sites. There was no significant differences between
oncology patients and controls on any of the major body
sites (Table I). However there was a highly significant in-
crease in distribution of naevi on palms or soles. Acral naevi
were present in 56 (21.3%) oncology patients in comparison
with 22 (8.4%) controls (P<0.0001), and among those with
acral naevi, median density was 18.0m-2 among survivors of
childhood cancer compared with 14.8 among controls. On
matched analysis, the odds of having received chemotherapy
if acral naevi were present, were nearly double the odds in
those who had no acral naevi, and this increase remained
significant in the adjusted relative odds (Table II). The
association was stronger in male cancer survivors, adjusted
relative odds = 2.4 (95% confidence interval 1.2, 4.9), and
while a positive association was observed in females between
treatment for cancer and acral naevi, it was not significant,
adjusted relative odds = 1.4 (0.6, 3.2). The increase in relative
odds of treatment for cancer was observed in all age groups,
though the association was weaker among children 5-14
years. The association was not observed among oncology
patients treated for Wilms' tumour. In the subgroup who had
completed chemotherapy the association was stronger thanNAEVI IN SURVIVORS OF CHILDHOOD CANCER 1055
Table I Median whole body naevus densities and ratio of paired densities among oncology patients
and control subjects
Median naevus densitiesa
All subjects
Sex
Males
Females
Number of
pairs
263
160
103
Ages
4 years 64
-14 181
> 15 18
Tumour type
Leukaemia 155
Wilms' tumour 23
Sarcomas 31
Other tumours 54
Chemotherapy status
On maintenance 101
Completed 162
Duration of treatment
< 1 month 23
2-12 months 96
> 12 months 144
Duration of remission
I year 40
-4 74
>4 47
Radiotherapy
No 122
Yes 141
*Chemotherapy
Prednisone
No 102
Yes 161
Alkylating agents
No 95
Yes 168
Antimetabolites
No 83
Yes 180
Mitotic inhibitors
No 11
Yes 252
Antitumour antibiotics
No 56
Yes 207
Anatomic region
Head and neck 263
Trunk 263
Arms 263
Legs 263
aMedian naevus density is naevus count m2
Oncology
patients
21.5
24.1
18.2
7.1
29.6
31.9
20.1
12.4
22.2
28.7
15.0
28.6
12.6
15.8
27.2
20.9
29.6
31.5
16.5
26.4
21.6
21.3
21.2
21.6
19.4
24.7
47.4
21.2
30.4
19.9
85.3
29.0
33.1
4.9
of body surface
Controls
19.5
19.7
19.5
6.4
27.1
32.8
20.2
21.1
19.5
16.2
14.2
25.8
12.4
19.5
21.4
19.5
31.7
25.5
15.8
24.5
19.7
19.1
19.1
19.7
16.4
22.2
20.3
19.3
21.2
19.1
62.9
29.0
30.6
7.1
Ratio' (range)
1.0 (0.0,31.9)
1.1 (0.0,31.9)
0.8 (0.0,27.6)
1.0 (0.0,21.1)
1.0 (0.0,31.9)
1.3 (0.2,19.4)
1.0 (0.0,31.9)
0.5 (0.0,2.1)
1.0 (0.0,19.4)
1.5 (0.0,7.8)
1.0 (0.0,31.9)
1.0 (0.0,27.6)
1.0 (0.0,12.0)
0.9 (0.0,19.2)
1.1 (0.0,31.9)
1.0 (0.0,16.8)
1.0 (0.0,27.6)
1.3 (0.1,19.4)
1.0 (0.0,21.1)
1.0 (0.0,31.9)
1.0 (0.0,19.4)
1.0 (0.0,31.9)
1.0 (0.0,27.6)
1.0 (0.0,31.9)
1.0 (0.0,19.4)
1.0 (0.0,31.9)
1.5 (0.3,5.7)
1.0 (0.0,31.9)
0.9 (0.0,11.6)
1.0 (0.0,31.9)
1.1 (0.0,524.8)
0.9 (0.0,100.4)
1.0 (0.0,154.5)
0.9 (0.0,94.9)
area. "P>0.05 for all comparisons.
among those currently receiving maintenance therapy (Table
II). As with whole-body naevus numbers, there was no obser-
vable difference in the proportion of oncology cases who had
acral naevi according to whether they had received any par-
ticular agent in their treatment regimen. There were
insufficient numbers to assess the distributions of acral naevi
in oncology patients at the outset ofchemotherapy compared
to matched controls, however the relative increase in
oncology patients was apparent, though not significant, after
only 1 month of chemotherapy (Table II).
Atypical naevi and melanoma
When prevalence of atypical naevi was considered separately,
30 (11%) of oncology patients were affected (one or more)
compared with 17 (6%) of controls (P = 0.047). In the sub-
group of children who had received less than 4 weeks'
chemotherapy however, no relative increase in atypical naevi
was present compared to matched controls. Adjustment for
the potential confounding effects ofcomplexion type and sun
exposure made no material difference to the results. Although
naevi were generally not subjected to histologic examination,
four suspicious lesions were biopsied from oncology patients,
during the study period. Three were benign naevi and the
fourth was a malignant melanoma which was removed from
a 17 year old boy some 13 years after he was treated for
rhabdomyosarcoma with chemotherapy and radiotherapy.
This was a level two melanoma on his back arising from a
pre-existing naevus, and was not in the radiation field. There
was no family history of melanoma, atypical moles or any
predisposing genetic condition. When examined by the
research nurse, he had four atypical naevi on his back, and
one on the sole of his foot. Based on standardised incidence
rates of melanoma among males in Queensland (Queensland
Cancer Registry, 1990), the risk of melanoma at this age in
the general population is less than one in 10,000.
Discussion
This is the largest study to date to investigate the association
between chemotherapy received in childhood and naevus
development. We examined approximately 90% of patients
who had ever received treatment for childhood cancer in
Queensland over the last two decades and compared the
occurrence of melanocytic naevi to that in controls of the1056 A. GREEN et al.
Table II Numbers of subjects with acral naevi, and the odds ofhaving received chemotherapy if acral
naevi were present relative to absent
Number of subjects
with acral naevi
Number of Oncology Relative odds of chemotherapy
Variable pairs patients Controls Crude Adjusteda (95% CLb)
L.oc L.0c
All subjects 263 56 22 1.9 1.9 (1.1,3.1)
Sex
Males 160 36 12 2.8 2.4 (1.2,4.8)
Females 103 20 10 1.2 1.3 (0.6,3.0)
Age
A4 years 64 1 1 3.0 3.2 (0.2,55.1)
- 14 181 48 21 1.8 1.6 (0.9,3.0)
>15 18 7 0 2.2 3.5 (0.8,15.4)
Tumour type
Leukaemia 155 37 14 1.9 1.7 (0.9,3.3)
Wilms' tumour 23 3 2 0.6 0.4 (0.0,3.4)d
Sarcomas 31 8 4 3.0 2.7 (0.5,14.3)
Other tumours 54 8 2 2.7 3.7 (0.8,17.0)
Chemotherapy status
On maintenance 101 14 10 1.9 1.3 (0.5,3.3)
Completed 162 42 12 1.9 2.1 (1.1,4.0)
Duration of treatment
< I month 23 3 1 2.5 2.9 (0.5,17.9)d
2-12 months 96 17 6 3.2 2.6 (0.8,8.1)
> 12 months 144 36 15 1.5 1.4 (0.8,2.6)
Duration of remission
I year 40 8 4 -
-4 74 21 6 2.4 2.6 (1.0,7.0)
>4 47 12 3 1.5 2.2 (0.8,6.4)
aAdjusted for skin colour, propensity to freckle, history ofsunburn, and time outdoors on weekends.
b95% confidence limits. cReference category for each variable is the subgroup with no acral naevi.
dAdjusted for all variables in (a) except for skin colour due to limited number ofpairs in analysis.. eNo
discordant pairs for analysis.
same sex and age. There was no apparent aAociation
between chemotherapy and the density of naevi overall in
Queensland, however the acral subsite showed a significantly
higher naevus density among childhood cancer survivors than
controls. This had been hypothesised a priori, based on
previous findings of a significant increase in acral naevi
among children who had been treated for cancer in England
(Hughes et al., 1989). In addition, childhood cancer patients
in Queensland who had received at least 4 weeks' chemo-
therapy had significantly more atypical naevi compared to
matched controls.
While previous findings have been suggestive of a general
association between chemotherapy and naevi, there is no firm
evidence. Two case-control studies which found a positive
association were based on relatively small numbers (Hughes
et al., 1989; de Wit et al., 1990), while in a follow-up study
which reported increased numbers of naevi in children 3
years after commencement of maintenance chemotherapy,
there were potential problems with the comparison subjects
who were ascertained some years earlier and whose naevi
were counted using different criteria, in a cross-sectional
study (Baird et al., 1992). Furthermore, all these studies
(Hughes et al., 1989; de Wit et al., 1990; Baird et al., 1992)
differed from the present study in that they were conducted
in populations with low background levels of sun exposure.
In Queensland children, a general association could indeed
exist between chemotherapy and naevi, but it may be over-
shadowed by the effect of solar ultraviolet radiation. The
very high overall prevalence of naevi in Queensland children
compared to English children, for example, has been noted
previously (Green et al., 1988), and presumably reflects the
large difference in ambient sun exposure in the two locations.
However, regardless of location, the palms and soles are
non-sunexposed sites, and it is reasonable to propose that
chemotherapy may play a role in the development of acral
naevi for which, like acral melanoma, causal factors are
unknown. The apparent modifications of the increase in acral
naevi in oncology patients by sex, by type of malignancy
treated, and by duration of treatment in the present study are
not easily explained and may be due to chance variation in
these small subgroups. The additional association with atyp-
ical naevi suggests thtat abnormal melanocytic proliferation
beyond the usual degree ofproliferation associated with com-
mon naevi after sun exposure, occurs after chemotherapy.
Mediation of the effect through the immune system has been
suggested by Hughes et al. (1989), and it may be relevant
that acral hyperpigmented macules are reported to-occur in
AIDS patients (Gallais et al., 1992). An increased number of
naevi found in 35 children with renal allografts compared
with age- and sex-matched controls in a recent study in
London (Smith et al., 1991) offers further support for an
immunosuppressive mechanism. Observation bias is unlikely
to explain the study results because the research nurses, while
not blinded to chemotherapy status, were unaware of any
subtype hypotheses.
It has been suggested that survivors of childhood cancer
should be especially counselled about the hazards ofexcessive
sun expogure in relation to risk of melanoma (Hughes et al.,
1989; Baird et al., 1992), and the occurrence of a melanoma
in one of our study subjects would support such precaution.
The development of this melanoma at an unusually young
age and the increased occurrence of atypical naevi also sup-
port the need to carefully examine pigmented skin lesions as
part of routine long-term surveillance of these children,
although our data did not show an association between
chemotherapy and naevi overall. The implications of a
specific increase in acral naevi are less clear. It may be that
these children are ultimately at risk of melanomas arising in
idiopathic acral naevi. The relationship between acral-lentig-
inous melanoma and acral naevi has been studied in Ugan-
dan Africans, but no direct association was observed (Lewis,
1968). However in view of the consistency in two analytic
studies of an apparent excess of acral naevi in childhood
cancer survivors, it may be appropriate to alert these patients
to the significance in later life of any changes in plantar
moles, since acral-lentiginous melanomas often have a poor
prognosis due to late diagnosis.
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